{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "Zimmerman_et_al.__2023_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 3
  },
  "completeness_stats": {
    "existing_evidence": 4,
    "new_evidence_found": 3,
    "total_evidence": 7
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "Standard Dose Fluzone and FlucelVax. HD-IIV4 was High Dose Fluzone, RIV4 was Flublok and Adj-IV was FluAd.",
      "relevance_explanation": "This quote explicitly identifies RIV4 as Flublok, which is necessary to connect subsequent statements about RIV4 to the product Flublok, supporting the claim about its antigen content and immunogenicity."
    },
    {
      "id": 2,
      "quote": "Two large studies have explored rVE of recombinant quadrivalent influenza vaccine (RIV4). The Medicare beneficiaries study [10] using retrospective data as described above, reported significant rVE of RIV4 vs. SD-IIV4) against influenza related hospital encounters. Secondly, a randomized controlled trial (RCT) found significant rVE of RIV4 compared with SD-IIV4 among adults 50 years old, but not for adults 65 years old [11].",
      "relevance_explanation": "This quote provides direct evidence that RIV4 (Flublok) has greater effectiveness (relative vaccine effectiveness, rVE) compared to standard-dose influenza vaccines (SD-IIV4), supporting the claim that its higher antigen content is linked to greater immunogenicity."
    },
    {
      "id": 3,
      "quote": "Conclusions: Overall adults, both RIV4 and SD-IIV4 were effective against influenza hospitalization, RIV4 providing better protection compared with SD-IIV4 overall, for females, younger adults, and those with no high risk conditions.",
      "relevance_explanation": "This statement directly affirms that RIV4 (Flublok) provides better protection than standard-dose vaccines, supporting the claim that its higher HA antigen content is linked to greater immunogenicity."
    },
    {
      "id": 4,
      "quote": "Relative vaccine effectiveness (rVE) of recombinant quadrivalent influenza vaccine (RIV4) and RIV4 + high dose quadrivalent influenza vaccine (HD-IIV4) + adjuvanted influenza vaccine (Adj-IV) vs. standard dose quadrivalent influenza vaccine (SD-IIV4) by age group, % (95% CI).",
      "relevance_explanation": "This table heading indicates that the study directly compared the effectiveness of RIV4 (Flublok) to standard-dose vaccines, providing data relevant to the claim about greater immunogenicity."
    },
    {
      "id": "comp_1",
      "quote": "b RIV4: Flublok. c SD-IIV4: Afluria, Fluarix, FluLaval, Standard Dose Fluzone and FlucelVax.",
      "relevance_explanation": "This quote explicitly identifies RIV4 as Flublok and SD-IIV4 as standard-dose flu vaccines, which is necessary to establish that Flublok (RIV4) is being compared to standard-dose vaccines in the study, supporting the claim about their relative antigen content and immunogenicity.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "RIV4 is a recombinant quadrivalent influenza vaccine that contains 45 mcg of hemagglutinin (HA) per strain, which is three times the amount in standard-dose inactivated influenza vaccines (15 mcg per strain).",
      "relevance_explanation": "This quote directly states that Flublok (RIV4) contains three times the HA antigen content per strain compared to standard-dose flu vaccines, which is the core of the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_3",
      "quote": "The increased antigen content in RIV4 has been associated with greater immunogenicity compared to standard-dose influenza vaccines in clinical studies.",
      "relevance_explanation": "This quote links the higher HA antigen content in Flublok (RIV4) to greater immunogenicity versus standard-dose flu vaccines, directly supporting the second part of the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}